Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2016 07:00 ET | Source: AveXis

AveXis Receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1

CHICAGO, July 20, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc., (Nasdaq:AVXS) a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
July 11, 2016 08:00 ET | Source: AveXis

AveXis Appoints Michael B. Johannesen as Senior Vice President, General Counsel and Chief Compliance Officer

CHICAGO, July 11, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
June 06, 2016 16:59 ET | Source: AveXis, Inc.

AveXis to Present at Goldman Sachs Annual Global Healthcare Conference and Jefferies 2016 Healthcare Conference

CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening...
May 16, 2016 08:00 ET | Source: AveXis, Inc.

AveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1

CHICAGO, May 16, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening...
May 12, 2016 16:01 ET | Source: AveXis, Inc.

AveXis Reports First Quarter 2016 Financial and Operating Results

Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1 Conference call May 12 at 4:30 p.m. EDT CHICAGO, May 12, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc....
May 06, 2016 15:10 ET | Source: AveXis, Inc.

AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1

-- Jerry Mendell, MD, Presented Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast Today at 4:30 p.m. Eastern Daylight...
May 05, 2016 08:00 ET | Source: AveXis, Inc.

AveXis to Report First Quarter 2016 Financial Results on Thursday, May 12

CHICAGO, May 05, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
April 25, 2016 08:00 ET | Source: AveXis, Inc.

AveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1

-- Jerry Mendell, M.D., to Present Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast on Friday, May 6, 2016 at 4:30 p.m....
March 16, 2016 16:01 ET | Source: AveXis, Inc.

AveXis Reports Fourth Quarter and Full Year 2015 Financial and Operating Results

-- Initial public offering raised $98.2 million in net proceeds -- -- Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1 – -- Conference call March 16...
March 08, 2016 08:00 ET | Source: AveXis, Inc.

AveXis to Report Full Year and Fourth Quarter 2015 Financial Results on Wednesday, March 16

CHICAGO, March 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...